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Cognitive decline in midlife 
A B S T R A C T   
Detection of incipient cognitive impairment and dementia pathophysiology is critical to identify preclinical 
populations and target potentially disease modifying interventions towards them. There are currently concerted 
efforts for such detection for Alzheimer’s disease (AD). By contrast, the examination of cognitive markers and 
their relationship to biomarkers for Vascular Cognitive Impairment (VCI) is far less established, despite VCI being 
highly prevalent and often concomitantly presenting with AD. Critically, vascular risk factors are currently 
associated with the most viable treatment options via pharmacological and non-pharmacological intervention, 
hence early identification of vascular factors have important implications for modifying dementia disease tra-
jectories. The aim of this review is to examine the current evidence of cognitive marker correlates to VCI pa-
thology. We begin by examining midlife risk factors that predict VCI. Next, discuss preclinical cognitive 
hallmarks of VCI informed by insights from neuropsychological assessment, network connectivity and ERP/EEG 
experimental findings. Finally, we discuss limitations of current cognitive assessments and the need for future 
cognitive test development to inform diagnostic assessment. As well as, intervention outcome measures for 
preclinical VCI. In turn, these tests will inform earlier detection of vascular changes and allow implementation of 
disease intervention approaches.   
1. Introduction 
Vascular Cognitive Impairment (VCI) is an umbrella term for con-
ditions related to disrupted cerebral blood flow to the brain and subse-
quent cognitive decline. Traditionally, post-stroke dementia was 
considered the main contributor to VCI, however it is now clear that it 
only represents a small portion of VCI, with other incipient neuro-
vascular changes (subcortical, multi-infarct and mixed dementias) 
significantly contributing to VCI [1]. This also dovetails with findings 
showing that up to 80% of dementia patients show vascular pathology at 
autopsy [2] [3] and there appears to be a reciprocal relationship be-
tween neurovascular and neurodegenerative pathology [4]. Impor-
tantly, cognitive decline in VCI can be insidious and evolve over many 
years without ‘classic’ stroke symptomology. In the next section, we will 
review current cognitive markers used in VCI before exploring 
preclinical cognitive measures and their neural correlates. 
The aim of this review is to examine the current evidence of cognitive 
marker correlates to VCI pathology. We outline the methods used for this 
narrative review and begin by discussing preclinical hallmarks of VCI 
informed by insights from neuropsychological assessment, network 
connectivity and ERP/EEG experimental findings used to detect cogni-
tive dysfunction in individuals at-risk of developing VCI. Lastly, we 
discuss limitations of current cognitive assessments and the need for new 
cognitive test development to inform diagnostic assessment and inter-
vention outcome measures for preclinical VCI. In these tests will inform 
earlier detection of vascular changes and allow implementation of 
existing disease intervention approaches. 
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2. Method 
Several procedures were followed to ensure a comprehensive review 
of the literature relevant to this narrative review. First, a review of peer- 
reviewed journals was undertaken using a wide range of key terms 
including; vascular cognitive impairment, preclinical vascular demen-
tia, midlife cardiovascular risks. Cross-sectional, longitudinal and 
retrospective studies were reviewed with a focus on experimental 
studies exploring midlife cognitive and anatomical brain changes, the 
reference section for each article was searched for additional relevant 
articles. Databases used included; Neurosynth, Science Direct, Psy-
cARTICLES, PsycINFO, PubMed and Google Scholar. The following 
publications were searched independently Stroke, Brain, Hypertension, 
NeuroImage clinical. For the purpose of this review, we define preclin-
ical VCI as a slowing or decline in cognitive or brain function which is 
associated with the presence of cardiovascular risk factors, before the 
expression of noticeable symptoms or a clinical criteria is met for VCI. 
We excluded articles containing diabetes type 1, CADISIL, CAA, post- 
stroke VCI. 
The literature review revealed, the most prevalent risk factors were 
hypertension, high cholesterol, diabetes type 2 and elevated BMI (see, 
Table 1.). These were deemed appropriate to investigate as they are a) 
identifiable with standard clinical assessment, b) modifiable with 
pharmacological or behavioural intervention and c) highly prevalent 
within the general population. Each risk factor was then reviewed with a 
search term postfix of dementia, vascular dementia, vascular cognitive 
impairment, cognition, cognitive decline, cognitive function, impair-
ment, midlife, middle age, preclinical, prodromal, brain change, visuo-
spatial, executive function, episodic memory, MRI, DMN, EEG, ERP, 
P300 P3, P3A and connectivity. Based on these findings we were able to 
establish associated cognitive functions affected in midlife and track the 
later life outcomes. The cognitive domains featured in the following 
sections (3.1 - 3.3) were established after this review of the literature 
which showed repeated deficits in these areas. 
3. Preclinical VCI 
There is a distinct lack of specificity on the diagnostic criteria for 
cognitive symptoms in VCI. Indeed, cognitive diagnostic tests in Alz-
heimer’s disease (AD) are largely based on episodic memory deficits, 
due to the initial impact of AD pathophysiology on medial temporal lobe 
structures. By contrast, lesion sites in VCI are more heterogeneous and 
hence symptoms can range from virtually none to multiple cognitive 
functions being affected. It is therefore not surprising that the charac-
terisation of cognitive deficits in VCI has been highly heterogenous to 
date. Detection of VCI specific changes in preclinical VCI is therefore 
even less established, despite offering significant treatment potential. 
A different approach is to outline which cardiovascular risk factors 
predict later-life cognitive impairment. Table 1. Clearly denotes that 
individuals with VCI risk factors in midlife show a cognitive decline 
overtime. Below, we review current, limited evidence on more domain- 
specific cognitive measures associated with established VCI risk factors 
and examine network connectivity and ERP/EEG contributions to 
explore potential strategies for the early identification of VCI. 
3.1. Executive function 
Cardiovascular risk is consistently associated with performance 
decline when high executive demands are required from participants, 
such as attention and processing speed, similar to clinical VCI and 
VASCOG criteria. For example, hypertension appears to have the biggest 
impact on executive function, motor speed and attention and this is most 
pertinent for hypertension at midlife but not at later-life[19]. Cognitive 
decline linked to hypertension was shown over a 20-year 
community-based cohort study[12]. The cognitive battery used in this 
study consisted of the Delayed Word Recall Test (DWRT), Digit Symbol 
Substitution Test (DSST) and Word Fluency Test (WFT) administered 
over three time points over 20 years. Results showed that, on composite 
scores, individuals on a hypertension spectrum had greater decline over 
the 20 year duration, compared to individuals with healthy blood 
pressure, and this effect was independent of age, sex, race, education, 
body mass index, diabetes mellitus, alcohol consumption, smoking sta-
tus, ApoE-ε4 genotype, and stroke history[11]. The Digit Symbol Sub-
stitution Test was the most sensitive measure to detect this decline. 
Baseline measures of the Digit Symbol Substitution Test at age 75 years 
have also been shown to predict the onset of more general cognitive 
decline, mobility and mood when adjusted for the presence of white 
matter hyperintensities[20]. Although the Digit Symbol Substitution 
Test is sensitive to the presence of wider cognitive dysfunction, it has 
low specificity. Indeed slower processing speeds as detected by this test 
may serve to identify disorders of cognition, mobility and even mood 
[21]. 
Other studies have explored the link of hypertension to processing 
speed, and the underlying neural changes. For example, it has been 
shown that hypertension amongst middle aged men (high systolic blood 
pressure >140 mm Hg) predicted lower grey matter volumes in the 
supplementary motor area, superior frontal gyrus, anterior cingulate 
cortex, and left middle temporal gyrus[22]. Low grey matter volume in 
the supplementary motor area also predicted slower completion times of 
the Trail Making Test (part B) and poorer recall of items from a 
four-word short-term working memory test, independent of age, total 
brain tissue volume, educational history, severity of carotid athero-
sclerosis, and the extent of periventricular and subcortical white matter 
lesions[22]. Similarly, diffusion tensor imaging (DTI) studies reported 
that people with hypertension showed significantly reduced integrity of 
white matter in the bilateral superior longitudinal fasciculus compared 
to healthy controls[23] impacting on their processing speed – this 
change being of particular interest given the propensity for injury to 
white matter tracts in clinically established VCI[24]. 
In addition to hypertension, older adults with type 2 diabetes have 
shown increased mean diffusivity, as measured via DTI, reflecting 
microstructural white matter abnormalities in the superior longitudinal 
fasciculus, the uncinate fasciculus, the inferior longitudinal fasciculus, 
and the genu and splenium of the corpus callosum[25]. This was asso-
ciated with reduced information processing speed (z scores of; Trail 
Making Test, Stroop Test, Digit Symbol Substitution Test) and worse 
verbal memory performance (Rey Auditory Verbal Learning Test) 
compared to age matched controls, independent of age, sex, estimated 
IQ, total white matter hyperintensity load, and presence of cerebral 
infarcts. Cognitive deficits in type 2 diabetic individuals have been 
found to be weaker in younger adults but still detectable[26], although 
poor glaucomic control seems to increase the severity of cognitive 
complaints[27]. Furthermore, in middle age individuals with type 2 
diabetes, white matter abnormalities have also been detected using DTI 
[28], despite no changes shown via resting state fMRI connectivity. 
Indicating more specific white matter alterations without necessarily 
affecting the functional connectivity of brain regions. Given that in-
dividuals with type 2 diabetes demonstrate greater structural abnor-
malities characteristic of VCI (white matter hyperintensities and lacunar 
infarcts) compared to healthy controls, it is promising that these changes 
appear to be associated with identifiable cognitive markers for symptom 
identification and tracking. 
The presence of executive function decline in VCI is also supported 
by findings from a prospective study examining changes to cerebral 
blood flow in healthy older adults with the APOE-ε4 allele dementia- 
risk-gene[29]. Results showed that APOE-ε4 allele carriers had lower 
cerebral blood flow, and the effects of this on cognitive performance 
(Trail Making Test and the Hopkins Verbal Learning Test) were made 
worse by the co-occurrence of hypertension. However, critically, in in-
dividuals with clinically significant hypertension, only those with lower 
cerebral blood flow demonstrated the negative association between 
APOE-ε4 and executive function on the Trail Making Test (part B), 
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Table 1 
Midlife VCI-Risk factors predictive of cognitive impairment.  
Study Type x‾ age at 
baseline 





Domain Summary Reference 
Retrospective 
cohort study 









non-specific Modifiable risk factors at midlife are 
predictive of later-life dementia 





Diabetes 200 mg/dL, 
sBP ≥140 mm Hg, 
dBP 90mm Hg, 
BMI 25–32%, 
APOE-ε4 carrier, 
Lower cognitive function 
25 MCI or Dementia 
diagnosis 
(unspecified) 
non-specific Cardiovascular risk factors and low 
cognitive function predict MCI and 





50 CAIDE risk score sig 
measures; Age >47yrs, 
Education <10yrs, 
sBP >140 mmHg, 
Total cholesterol 6•5 
mmol/L, 
BMI >30KG/M2, 
Inactivity <30mins p/w, 
APOE-ε4 carrier 
Sex: male 
21 Diagnosis of 
dementia 
(unspecified) 
non-specific Midlife cardiovascular risk predicts 





58 Higher lipid level: total 
cholesterol (200–239 mg/ 
dL) and triglycerides 
(200–500 mg/dL) 
LDL; 130–159 mg/dL and 
160–189 mg/dL 








Midlife elevated lipid level predictive 
of 20-year decline on cognition. 
Association of high LDL and 
triglycerides greater in DWRT with 
APOE- ε4 
Elevated midlife LDL predictive of 
selective cognitive decline  
Power et al  
[8]. 
Meta-analysis 54 BMI 27.58 kg/m2 
sBP 120.26mm Hg 
dBP 73.27mm Hg 
Total Cholesterol 214.99 
mg/dL, Glucose level 
107.21 mg/dL 
20 Composite score 







Composite score cardiovascular risk 
associated with declined cognitive 











sig, VaD trend) 
non-specific 57% greater risk of AD 
26% greater risk of VaD 
50% greater of VaD 





57 Hypertension sBP >140 
mmHg, dBP 90 mm Hg  
Prehypertension sBP 
>120mm Hg, dBP ns  
20 Z-scores; DWRT, 
DSST, WFT   
DSST 




Midlife hypertension predicts 
cognitive decline, DSST most sensitive 
to preclinical stage. Yet, elevated 
blood pressure at late life was not 
associated with cognitive decline 
Gottesman 
et al [11]. 
Epidemiology 
cohort study 
25 Hypertension (BP 
variability) 
25 DSST, RAVLT  Processing speed, 
sustained attention, 
verbal memory 
Long-term BP variability for 25 years 
beginning in young adulthood was 
associated with worse psychomotor 
speed and verbal memory tests in 
midlife. Stroop test lacked sensitivity 




71 Prediabetes HbA1c level 
≥5.8% 
Diabetes HbA1c level 
≥7.1% 
9 MMSE General cognition Prediabetes and diabetes at 71 were 
independently associated with 





≥50 Diabetes HbA1c level 
≥6.5% 
8 Diagnosis of 
dementia 
(unspecified) 
Non-specific Diabetes at midlife increases the risk 
of dementia at follow up 




62 Diabetes HbA1c level 
≥6.68% 
14 DSST Executive function, 
processing speed, 
sustained attention 
DM at midlife affects cog flexibility 
and visuospatial abilities but not 
memory. Word List and Mosaic Task 
lacked sensitivity 




57 Diabetes HbA1c level 
≥6.5% 




DM at midlife associated with 
significant cognitive decline over 20 
years compared to controls 
Rawlings et 
al [16]. 
Meta-analysis 50 BMI ≥25KG/M2 3–36 AD and VAD 
diagnosis 
non-specific Overweight in midlife associated with 
dementia but continuous BMI in late- 
life was not associated with dementia 
Anstey et al  
[17]. 
36–43 30 
(continued on next page) 
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compared to individuals with higher cerebral blood flow. Yet, there was 
no interaction between hypertension, APOE-ε4 and cerebral blood flow 
with respect to the memory recall measured by the Hopkins Verbal 
Learning Test[29], suggesting that hypertension in individuals at risk of 
dementia with lower cerebral blood flow impairs executive function 
selectively. This also implies that greater cerebral blood flow may act as 
a protective factor against cognitive deficits in APOE-ε4 individuals. 
This is further confirmed by a cluster analysis investigating the impli-
cation of hypertension on cognition, mood and mobility in healthy older 
adults[30]. Results showed an association between hypertension, 
reduced Trail Making Test (part B) performance, depressive symptoms 
and slower speed. Whereas, consistent with more recent findings, 
memory measures (Hopkins Verbal Learning Test; immediate recall, 
delayed recall and recognition) did not reveal such associations[30]. 
This therefore illustrates that visuospatial and set-shifting deficits in 
individuals at high cardiovascular risk can serve as a potential cognitive 
marker of VCI, but memory tests may be less sensitive. 
Finally, individuals with high composite cardiovascular risk scores 
also show increased activation change in the left parietal cortex, asso-
ciated with greater executive demand in the Flanker task, compared to 
low risk persons[31], establishing a connection between aggregated 
cardiovascular risk and parietal-mediated cognitive deficits. This nicely 
dovetails with the DTI findings in the superior longitudinal fasciculus 
and is consistent with the view that VCI cognitive and functional 
impairment is frequently more fronto-parietal in nature, as opposed to 
hippocampal-dependant episodic memory problems that are tradition-
ally associated with AD. 
3.2. Visuospatial function 
Besides the prevalent executive function changes, VCI also often 
presents clinically with visuospatial deficits, this also seems true before 
the onset of clinical symptoms. For example, findings from a longitu-
dinal cohort study suggests a steeper decline in visuospatial performance 
with age for individuals diagnosed with diabetes type 2 at midlife, 
compared to those diagnosed at a later stage[15]. For those individuals 
with midlife diabetes, decline over time was observed for the digit 
symbol test and for visuospatial imagery (where participants are 
required to count the surfaces of three-dimensional geometrical figures), 
compared to individuals diagnosed at a later stage[15]. Assessments of 
word fluency, visual search and verbal recall tasks did not reveal any 
deficits, suggesting a specific effect of long-term type 2 diabetes in do-
mains of visuospatial processing and processing speed, but not memory. 
White matter hyperintensity volume in healthy mid-life adults has 
also been associated with reduced visuospatial abilities, as assessed 
using the Hooper Visual Organisation Test[32]. Visuospatial memory 
and organization performance were worse in participants with greater 
white matter hyperintensity volumes, as compared to participants with 
low white matter hyperintensity volumes. A similar pattern of perfor-
mance was observed for visual scanning and motor speed, assessed by 
the Trail Making Test. In contrast, verbal memory, abstract reasoning 
and naming showed no significant differences between individuals with 
low versus high volume white matter hyperintensity. 
Further research shows that young adults with a family history of 
hypertension (first degree relative systolic with blood pressure >140 
mmHg before 60 years old) also have different neural activations during 
a visuospatial n-back task, compared to controls, despite equivalent task 
performance[33]. Relative to controls, individuals with a family history 
of hypertension exhibited lower activation to the visuospatial n-back 
task in the right inferior parietal lobule and the right inferior temporal 
gyrus, and substantially more deactivation in the posterior cingulate 
[33], indicating subtle changes in visuospatial mechanisms in healthy 
individuals with a predisposition to VCI risk-factors. 
3.3. Episodic memory 
Deficits in episodic memory are less often associated with VCI and 
more apparent in AD. However, there have been some interesting 
findings from studies with at VCI-risk individuals, suggesting that brain 
regions involved in episodic memory are also affected by early neuro-
vascular change. In a cross-sectional study, reduced scores in immediate 
and delayed Emotional Memory and free recall in the California Verbal 
Learning Test were found in middle aged individuals with type 2 dia-
betes, compared to healthy controls. In contrast, working memory, 
sustained attention and verbal fluency were unaffected[34]. DTI anal-
ysis showed that white matter microstructural abnormalities were pre-
sent amongst individuals with diabetes and were predominantly located 
in the frontal and temporal regions, particularly the left temporal stem 
[34]. These DTI findings may explain the lower memory performance 
present amongst diabetics, after accounting for age, metabolic dysre-
gulation and hypertension. This is supported by a further cross-sectional 
study indicating that older adults with type 2 diabetes had poorer per-
formance on the Rey Complex Figure Test (memory recall condition) 
and longer completion times in the Stroop test[35]. These results were 
associated with grey matter loss in the anterior cingulate and medial 
frontal lobes, and with white matter loss in frontal and temporal regions. 
Interestingly, longer diabetes duration (≥15yrs) was associated with 
impairments in visuospatial and inhibition domains, with reduced per-
formance in the Rey Complex Figure Test (copy condition), digit symbol 
coding and digit search over time[35]. 
In addition, older adults with greater cardiovascular burden have 
been shown to have an accelerated decline in episodic memory, working 
memory, and perceptual speed over time compared to lower risk in-
dividuals[36]. Episodic memory was assessed using Word List Memory, 
Word List Recall, Word List Recognition and immediate and delayed 
recall of the Wechsler Memory Scale-revised. Working memory was 
evaluated using the Digit Span and digit ordering tasks. Perceptual speed 
was tested using the Symbol Digit Modalities Test, Number Comparison, 
and 2 indices from a modified Stroop Test. MRI analysis revealed that 
reduced episodic and working memory performance was associated with 
smaller volumes of the hippocampus, whilst reduced perceptual speed 
was linked to greater volume of white matter hyperintensities[36]. This 
is supported by an earlier study examining cognition in mild cognitive 
impairment (MCI) individuals with hippocampal atrophy compared 
with MCI individuals with severe white matter hyperintensities. Results 
show equally impaired episodic memory performance (using an 
object-colour association task) for both groups but with additional 
impairment for the MCI individuals with white matter hyperintensities 
Table 1 (continued ) 
Study Type x‾ age at 
baseline 

















Longer exposure to elevated BMI and 
greater waist circumference at midlife 
associated with lower cognitive 
function at 60yrs 
Masi et al  
[18]. 
BMI = body mass index, sBP = systolic blood pressure, dPB = diastolic blood pressure, APOE-ε4 = Apolipoprotein E subtype 4, LDL = low-density lipoproteins, HbA1c 
= hemoglobin A, DWRT = Delayed Word Recall Test, DSST = Digit Symbol Substitution Test, WFT = Word Fluency Test, RAVLT = Rey Auditory Verbal Learning Test, 
TMT = Trail Making Test, MMSE = Mini Mental State Examination. 
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in tests tapping verbal and spatial working memory abilities and 
attentional control processes[37]. This potentially suggests white matter 
hyperintensities reflect disruption to the white matter tracts (dorsolat-
eral prefrontal cortex and connected neural circuits), which result in 
diminished executive control processes critical to working memory, that 
may in turn impair episodic memory function[37]. 
This account of insidious pathology in VCI-risk populations indicates 
that early manifestations of VCI may also span medial temporal and 
related networks. However, at this stage it is unclear whether these 
episodic memory impairments are in line with age-related memory 
decline, concomitant AD or a collateral effect of VCI. Regardless, it 
emerges that the cognitive changes in preclinical VCI might more affect 
networks of brain regions, instead of discrete areas, in particular when 
white matter tracts are affected. In the following section we will review 
therefore how potentially the network connectivity between brain re-
gions might be affected in preclinical VCI and how this will impact on 
the cognitive symptomology. 
4. Network connectivity 
4.1. fMRI 
Disruptions to the default mode network (DMN) is of major interest 
in preclinical dementia. The DMN consists of a network with three major 
subdivisions: the ventral medial prefrontal cortex, the dorsal medial 
prefrontal cortex and the posterior cingulate cortex and adjacent pre-
cuneus plus the lateral parietal cortex[38][39] that co-activate when 
subjects are at rest and de-activate when subjects become engaged in 
external cognitive tasks. It is thought that DMN dysconnectivity could 
represent a biomarker for preclinical AD and this may be related to 
cerebrovascular function[40][41]. Cerebrovascular reactivity was 
significantly reduced in the posterior cingulate/precuneus and anterior 
cingulate areas of the DMN for those with hypertension and pre-
hypertension (defined as either systolic blood pressure >= 130 mmHg, 
diastolic blood pressure >= 85 mmHg or use of blood pressure medi-
cation) as compared to healthy controls[41]. Similarly, MCI patients 
with evidence of cerebrovascular infarcts also showed differing under-
lying (de)activation patterns compared to MCI individuals free from 
infarcts, during an n-back task, even though neuropsychological scores 
were similar[42]. Results indicate impaired deactivation in the pre-
cuneus/ posterior cingulate cortex, for those MCI individuals with in-
farcts. Additionally, greater activation was observed in the anterior 
cingulate gyrus during differing memory loads compared to MCI pa-
tients without infarcts. To suggest a differing working memory load 
fMRI response between groups and potentially indicating different DMN 
connectivity for preclinical VCI individuals as compared to early stage 
AD individuals and would also nicely dovetail with the white matter 
changes reported in preclinical VCI (though see, [43]). 
Frontal networks, including the salience network primarily 
composed of the anterior insula and the dorsal cingulate cortex, 
involved in sustained attention and task switching, have also been 
implicated in dysconnectivity in MCI individuals with elevated mean 
systolic blood pressure (150 mmHg), compared to healthy aged matched 
controls[40]. The resting state fMRI study in MCI, healthy age matched 
controls and young adults showed that the salience network, particu-
larly its dorsal sub-network, modulates the interactions between the 
DMN and the central executive network in young adults and healthy 
ageing. This pattern of modulation in the salience network was inter-
rupted in MCI and the degree of disruption was associated with lower 
overall cognitive scores on the MoCA[40]. Importantly, the authors 
commented that the effect was particularly pronounced in the MCI in-
dividuals due to their elevated blood pressure and more pervasive ‘ex-
ecutive’ impairments assessed by the MoCA, TMT, Stroop interference 
and verbal frequency. Based on these findings, salience network changes 
might be indicative of measuring frontally mediated executive impair-
ment and asocial vascular pathophysiology in MCI. This would also 
dovetail with findings showing that dysfunction to the DMN/ salience 
networks and associated functional impairment may be predictive bio-
markers of later-life VCI[44] [45],. 
4.2. ERP/EEG 
Network dysfunction can not only be measured via fMRI but also via 
EEG derived measures such as event-related potentials (ERPs) or fre-
quency analyses. This approach has been successfully employed to pa-
tients presented with clinical dementia syndromes[46]. The P300 
component in particular, has been suggested as a physiological marker 
of preclinical AD[47]. P300 is thought to be evoked by the rapid 
detection of environmental changes and is associated with domains of 
working memory as well as attention and characterized by a positive 
deflection with a latency between 250 and 500ms[48]. A classic para-
digm for evoking the P300 response is the oddball task, where partici-
pants have to detect rare stimuli amongst frequently occurring standard 
stimuli. ‘Oddball’ target stimuli typically evoke a response that is 
maximal at parietal electrode sites (P3b), whilst novel stimuli evoke a 
response that is maximal at frontal sites (P3a [49];). These novel and 
target P300 components can be used to evaluate cognitive decline[47] 
and evidence suggests that decreased P300 amplitude is associated with 
reduced language, memory and executive function performance in AD 
[48]. Additionally, non-clinical older adults with reduced cognitive 
ability (MoCA score <25) demonstrate reduced P300 amplitude 
compared to age matched controls and healthy young adults[50]. 
Reduced P300 latencies have also been observed in MCI and in AD, 
compared to healthy controls (for a review see, [51]). 
Importantly, one study reported that VCI and AD could be differen-
tiated by including novel stimuli in an auditory oddball paradigm[52]. 
Results showed that the novel P300 amplitude (P3a) was markedly 
reduced in VCI patients, but that it was preserved in AD and controls 
[52]. Further, source localisation studies indicate that VCI patients have 
an impaired parietal-to-frontal and parietal-to-central connectivity 
during the oddball paradigm (200–300 ms after stimuli onset) compared 
to controls, showing a weakened outgoing connectivity from parietal 
regions[53][54]. This response appears different compared to AD 
groups where a shift of maximum intensity location during the P300 
response occurs from the frontal-to-temporal lobes[55]. The P300 
component could also be a promising biomarker in preclinical in-
dividuals as the ‘oddball’ response in middle age type 2 diabetics[56] 
and hypertensive older adults[57] includes increased P300 latencies 
compared to healthy controls. Taken together, the evidence suggests this 
differing ERP response may reflect dysconnectivity between posterior 
and anterior structures in at VCI-risk individuals – reminiscent of white 
matter tract dysfunctions in preclinical and clinical VCI individuals. 
Below, in Fig. 1. we have provided a schematic illustration of the brain 
regions implicated at the prodromal stage of VCI and a potential pre-
liminary model of emerging disconnectivity. 
5. Conclusion and outlook 
There is clearly a disconnect between well-established neural 
markers of VCI and how they relate to cognitive symptomology. This 
may be explained by the current lack of a gold standard or single domain 
cognitive measures to detect VCI, either clinically or preclinically. 
Instead current cognitive measures lack the specificity to isolate VCI 
pathology and sensitivity to detect its earliest symptoms. This might not 
be a problem per se, however clinically a functional readout of how 
symptoms change over time, including cognitive problems, is important 
for disease prevention, management, and tracking. 
Taken together, the reviewed evidence suggests that impaired ex-
ecutive function, visuo-spatial and set-shifting ability along with dys-
connectivity between the frontal-parietal networks and subcortical 
structures (cingulate, insula and precuneus) may predict VCI onset. The 
VASCOG guidelines[58] highlight that disturbances to frontal and 
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executive processes (slowed information processing, reduced 
set-shifting ability and poorer working memory) are prominent in VCI. 
Although this contributes towards identifying the cognitive and bio-
logical markers of preclinical VCI, the current clinical measures (MoCA, 
TMT, DSST…) might not be sensitive or specific enough to detect the 
earliest VCI changes or disassociate it from incipient AD pathophysi-
ology (see, Table 2. for the neural substrates of typical cognitive 
symptoms of VCI compared to AD). Instead, more experimental mea-
sures informed by preclinical neural and cognitive change need to be 
explored to fill the gaps in this research area and aid our understanding 
of biomarker development of this insidious multifaceted disease. 
However, one particularly striking aspect emerging from our review 
is that despite parietal functions, areas, and connections being 
commonly affected in VCI, cognitive and neural measures rarely tapped 
into those. In addition, the superior longitudinal fasciculus (white 
matter tract connecting parietal, temporal with prefrontal regions) is 
heavily implicated in underpinning executive function[59] but also 
likely plays into parietal dysfunction in VCI. Interestingly, this white 
matter tract is also thought to play a role in spatial processing[60]. As 
such, investigations into parietal mediated spatial orientation could be a 
potentially novel and more specific approach towards VCI and may help 
to discriminate between VCI and AD pathology. In a recent study, we 
have showed that indeed egocentric (self-referential) spatial orientation 
has sensitivity and selectivity to VCI and can be used as a measure to 
differentiate between VCI and AD patients[61]. This is supported by an 
earlier case study suggesting that egocentric orientation deficits, medi-
ated by fronto-parietal structures, may be a promising marker for the 
identification of vascular pathology[62]. This coupled with MRI and 
ERP experimental findings from VCI and at-risk individuals may mark a 
promising path forward for the development of selective markers 
focused on connectivity changes across key brain structures. 
Although neuroimaging is less accessible for clinical utility, it is clear 
network approaches should be explored to identify at VCI-risk in-
dividuals to help inform more selective cognitive testing. Although, this 
area of research is in its infancy the present review suggests neuropsy-
chological assessments which tap into structures affected at the pre-
clinical stage of VCI (see, outcome measures listed in Table. 1) are more 
appropriate for diagnostic and screening purposes compared to more 
multi-domain assessments. Yet, new and novel methods assessing self- 
referential spatial navigation seem to have greater selectivity and 
specificity than more traditional pen and paper tasks (see, [61]). 
However, the current review is not without limitation. VCI is highly 
heterogenous in terms of expression, as well as pathogenesis. Therefore, 
have not considered the complex interaction of risk factors (for review, 
see [63]), or how they may contribute towards potential different ex-
pressions of preclinical VCI. Nor, have we discussed the latter stages of 
VCI at its clinical threshold or how specific lesion sites may be incor-
porated into our preliminary model (see, Fig. 1) of prodromal change. 
This is due to this review being focused on modifiable mechanisms that 
contribute to cerebrovascular change with an aim to identify their 
cognitive fingerprints at an early stage. However, longitudinal tracking 
of the risk factors, along with cognitive and neuroimaging markers 
discussed above, may help identify at-risk individuals and a potential 
‘sensitive window’ to deduce if/or when symptomology could be slowed 
or halted with appropriate intervention. We also acknowledge that the 
body of literature examining cognitive and neuroimaging correlates of 
risk factors that predate VCI is limited and has highlighted the need for 
further resources and investigation to gain a broader understanding of 
the preclinical stage. 
Growing evidence indicates that cardiovascular risk factors are 
associated with increased structural and metabolic change in the brain, 
worse cognitive performance and increased dementia risk. Yet, research 
is still lacking in detecting these symptoms in preclinical individuals 
before presentation of frank VCI. However, from the research discussed 
throughout this review there appears to be an emergence of cognitive 
dysfunction and connectivity changes in at VCI-risk individuals and as 
Fig.. 1.. Schematic illustration of brain regions implicated and potential model of disconnectivity emerging between parietal sites and connecting anterior regions. 
Brain image courtesy of Servier Medical Art https://smart.servier.com/. 
Table 2 
Typical neural substrates of cognitive symptoms of VCI compared to AD.   
Frontal Parietal Temporal 
VCI +++ ++ +
AD + + +++
Strength of symptoms, + low; ++ moderate; +++ high. 
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such, a more subtle and sophisticated approach is required to detect 
these biological and behavioural markers in their earliest manifesta-
tions. Focusing investigation into new and novel screening techniques to 
detect this dysfunction is key to providing clinical utility in order to 
identify, intervene and track disease progression as well as personalise 
treatment pathways. 
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